Eslam Ahmed Habba
Tanta University, Egypt
Title: Hepatoma recurrence after Radiofrequency Ablation (RFA) in Egyptian patients with HCV
Biography
Biography: Eslam Ahmed Habba
Abstract
Radiofrequency ablation (RFA) is the treatment of choice for patients with an early-stage Hepatocellular Carcinoma (HCC) who are not candidates for surgical management; however, it is associated with a recurrence rate as high as 15–30% after one year. The aim of this study was to analyze the risk factors for HCC recurrence in Egyptian patients after RFA. This study was conducted on 45 HCC patients presented at two large referral centers for management of HCC in Egypt. Only patients with an early-stage HCC, eligible for RFA, were included in the analysis and were followed up for a period of one year and grouped into 2 groups: Group I which included patients with HCC recurrence during follow-up (n=30) and Group II with patients who did not show any recurrence during follow-up (n=15). The risk factors associated with recurrence included smoking (70% in Group I vs. 40% in Group II), hepatomegaly (50% in Group I vs. 40% in Group II), splenomegaly (90% in Group I vs. 53.3% in Group II), heterogeneous liver (30% in Group I vs. 6.66% in Group II), bilobar involvement (20% in Group I vs. 6.66% in Group II), and tumors in contact with hepatic capsule (20% in Group I vs. 6.66% in Group II). Hepatomegaly, liver heterogeneity, and splenomegaly (a sign of portal hypertension) together with the tumor factors such as large size, bilobar involvement, and proximity to liver capsule were the factors that showed a significant association with tumor recurrence in this study.